{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T05:47:49Z","timestamp":1745300869087},"reference-count":58,"publisher":"Impact Journals, LLC","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2021,9,15]]},"DOI":"10.18632\/aging.203314","type":"journal-article","created":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T19:35:47Z","timestamp":1631388947000},"page":"21102-21121","source":"Crossref","is-referenced-by-count":4,"title":["Bortezomib enhances the anti-cancer effect of the novel Bruton\u2019s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK"],"prefix":"10.18632","volume":"13","author":[{"given":"Xianhuo","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Fei","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengzi","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiubao","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiongli","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanfang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1182\/asheducation-2007.1.270","article-title":"Mantle cell lymphoma: identifying novel molecular targets in growth and survival pathways.","volume":"200","author":"O'Connor","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-020-00855-9","article-title":"Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.","volume":"1","author":"Kim","year":"2020","journal-title":"J Hematol Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.","volume":"11","author":"Berrino","year":"2010","journal-title":"Blood"},{"key":"4","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.","volume":"10","author":"Roman","year":"2011","journal-title":"Br J Cancer"},{"key":"5","doi-asserted-by":"publisher","first-page":"112516","DOI":"10.18632\/oncotarget.22367","article-title":"Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas.","volume":"8","author":"Du","year":"2017","journal-title":"Oncotarget"},{"key":"6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/107327481201900307","article-title":"Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.","volume":"1","author":"Sotomayor","year":"2012","journal-title":"Cancer Control"},{"key":"7","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma.","volume":"13","author":"Maddocks","year":"2018","journal-title":"Blood"},{"key":"8","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.","volume":"7","author":"Palomero","year":"2012","journal-title":"Cancer Res"},{"key":"9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","article-title":"Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis.","volume":"9","author":"Hsi","year":"2011","journal-title":"Haematologica"},{"key":"10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/modpathol.2017.135","article-title":"CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.","volume":"3","author":"Jorgensen","year":"2018","journal-title":"Mod Pathol"},{"key":"11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13046-017-0652-8","article-title":"Smoldering mantle cell lymphoma.","volume":"3","author":"Wang","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"12","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","volume":"12","author":"Jaffe","year":"2016","journal-title":"Blood"},{"key":"13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.","volume":"11","author":"Wiestner","year":"2011","journal-title":"Blood"},{"key":"14","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.","volume":"7","author":"Campo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"15","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1182\/blood-2018-02-832535","article-title":"SOX11 augments BCR signaling to drive MCL-like tumor development.","volume":"13","author":"Parekh","year":"2018","journal-title":"Blood"},{"key":"16","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/leu.2015.355","article-title":"SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6.","volume":"3","author":"Amador","year":"2016","journal-title":"Leukemia"},{"key":"17","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.","volume":"13","author":"R\u00e4ty","year":"2017","journal-title":"Blood"},{"key":"18","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma.","volume":"12","author":"Campo","year":"2012","journal-title":"J Clin Invest"},{"key":"19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies.","volume":"3","author":"Hamdy","year":"2013","journal-title":"J Clin Oncol"},{"key":"20","first-page":"120","article-title":"The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective.","volume":"17","author":"Witte","year":"2000","journal-title":"Immunol Rev"},{"key":"21","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.2013.53.1046","article-title":"Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.","volume":"3","author":"Burger","year":"2014","journal-title":"J Clin Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.","volume":"12","author":"Tam","year":"2014","journal-title":"Blood"},{"key":"23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.cjca.2017.12.001","article-title":"Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib.","volume":"3","author":"Jones","year":"2018","journal-title":"Can J Cardiol"},{"key":"24","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1080\/10428194.2018.1457149","article-title":"Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System.","volume":"5","author":"Jones","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"25","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.","volume":"12","author":"Payrastre","year":"2014","journal-title":"Blood"},{"key":"26","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.","volume":"12","author":"Bilotti","year":"2015","journal-title":"Blood"},{"key":"27","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.","volume":"37","author":"Devereux","year":"2015","journal-title":"N Engl J Med"},{"key":"28","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bjh.15108","article-title":"Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.","volume":"18","author":"Shpilberg","year":"2018","journal-title":"Br J Haematol"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Lee J, Zhang LL, Wu W, Guo H, Li Y, Sukhanova M, Venkataraman G, Huang S, Zhang H, Alikhan M, Lu P, Guo A, Galanina N, et al. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv. 2018; 2:2039-51. https:\/\/doi.org\/10.1182\/bloodadvances.2018016048.","DOI":"10.1182\/bloodadvances.2018016048"},{"key":"30","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.","volume":"18","author":"Badillo","year":"2018","journal-title":"Br J Haematol"},{"key":"31","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma.","volume":"12","author":"Noto","year":"2016","journal-title":"Blood"},{"key":"32","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1182\/blood.V126.23.832.832","article-title":"The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed\/Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial.","volume":"12","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"33","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1158\/1538-7445.AM2015-2597","article-title":"BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor.","volume":"7","author":"Wang","year":"2015","journal-title":"Cancer Research"},{"key":"34","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1182\/blood.V128.22.642.642","article-title":"Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)\/Small Lymphocytic Lymphoma (SLL).","volume":"12","author":"Kirschbaum","year":"2016","journal-title":"Blood"},{"key":"35","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1182\/blood.V128.22.1216.1216","article-title":"High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study.","volume":"12","author":"Kirschbaum","year":"2016","journal-title":"Blood"},{"key":"36","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.","volume":"13","author":"Tedeschi","year":"2019","journal-title":"Blood."},{"key":"37","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.","volume":"2","author":"Gao","year":"2020","journal-title":"Clin Cancer Res"},{"key":"38","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood.2020006449","article-title":"Zanubrutinib for the treatment of patients with Waldenstr\u00f6m macroglobulinemia: 3 years of follow-up.","volume":"13","author":"Novotny","year":"2020","journal-title":"Blood"},{"key":"39","doi-asserted-by":"publisher","first-page":"6706","DOI":"10.1038\/sj.onc.1209933","article-title":"Transcriptional regulation via the NF-kappaB signaling module.","volume":"2","author":"Ghosh","year":"2006","journal-title":"Oncogene"},{"key":"40","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.","volume":"2","author":"Shi","year":"2009","journal-title":"Ann Oncol"},{"key":"41","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.","volume":"2","author":"Shi","year":"2006","journal-title":"J Clin Oncol"},{"key":"42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2141.2008.07466.x","article-title":"Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.","volume":"14","author":"Blumel","year":"2009","journal-title":"Br J Haematol"},{"key":"43","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.","volume":"37","author":"Drach","year":"2015","journal-title":"N Engl J Med"},{"key":"44","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1002\/cncr.31361","article-title":"Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.","volume":"12","author":"Pro","year":"2018","journal-title":"Cancer"},{"key":"45","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","article-title":"Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.","volume":"1","author":"Hu","year":"2018","journal-title":"Lancet Oncol"},{"key":"46","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3324\/haematol.2018.191429","article-title":"A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.","volume":"10","author":"Mounier","year":"2019","journal-title":"Haematologica"},{"key":"47","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.","volume":"6","author":"Anderson","year":"2001","journal-title":"Cancer Res"},{"key":"48","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.1002\/cam4.2565","article-title":"Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.","volume":"8","author":"Min","year":"2019","journal-title":"Cancer Med"},{"key":"49","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.","volume":"3","author":"Simpson","year":"2020","journal-title":"Leukemia"},{"key":"50","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study.","volume":"13","author":"Tedeschi","year":"2020","journal-title":"Blood"},{"key":"51","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/ijc.29326","article-title":"Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.","volume":"13","author":"Baran-Marszak","year":"2015","journal-title":"Int J Cancer"},{"key":"52","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","article-title":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.","volume":"3","author":"Alkan","year":"2013","journal-title":"Leuk Res"},{"key":"53","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/bjh.12573","article-title":"Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.","volume":"16","author":"Advani","year":"2013","journal-title":"Br J Haematol"},{"key":"54","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.","volume":"37","author":"Ghia","year":"2016","journal-title":"N Engl J Med"},{"key":"55","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ceb.2004.09.010","article-title":"Coordination of cell death and the cell cycle: linking proliferation to death through private and communal couplers.","volume":"1","author":"White","year":"2004","journal-title":"Curr Opin Cell Biol"},{"key":"56","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1182\/blood-2013-05-504597","article-title":"Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing.","volume":"12","author":"Muthusamy","year":"2013","journal-title":"Blood"},{"key":"57","doi-asserted-by":"publisher","first-page":"S196","DOI":"10.1016\/S0049-3848(16)30187-6","article-title":"PO-54 - Clinical and laboratory characterization of platelet dysfunction caused by ibrutinib treatment in patients with chronic lymphocytic leukemia.","volume":"14","author":"De Candia","year":"2016","journal-title":"Thromb Res"},{"key":"58","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/s0006-2952(02)01154-1","article-title":"Nuclear factor-kappa B and cancer: its role in prevention and therapy.","volume":"6","author":"Aggarwal","year":"2002","journal-title":"Biochem Pharmacol"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.203314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T14:50:33Z","timestamp":1632149433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.203314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":58,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,9,15]]}},"alternative-id":["203314","34508613"],"URL":"https:\/\/doi.org\/10.18632\/aging.203314","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,10]]}}}